Distribution

Albumin is the most abundant plasma protein, with a normal concentration of 3.5 to 5.0 grams per deciliter. It is the principal binding protein for acidic drugs: warfarin, phenytoin, valproic acid, furosemide, and most nonsteroidal anti-inflammatory drugs bind extensively to albumin. Alpha-1-acid glycoprotein is an acute-phase reactant protein present at lower concentrations than albumin and is the primary binding protein for basic drugs: lidocaine, propranolol, methadone, tricyclic antidepressants, and many opioids bind preferentially to alpha-1-acid glycoprotein.

This protein-class pairing matters clinically because albumin and alpha-1-acid glycoprotein concentrations change in opposite directions during acute illness. Albumin falls in critical illness, surgery, hepatic disease, and nephrotic syndrome. Alpha-1-acid glycoprotein rises as an acute-phase reactant during the same acute illnesses. The net effect on drug binding depends on which protein binds the drug in question.

Only the unbound (free) drug fraction produces pharmacological effects, crosses membranes, and is available for hepatic metabolism and renal filtration. This principle — the free drug hypothesis — has a direct and commonly misunderstood consequence for therapeutic drug monitoring: standard drug assays measure total plasma drug concentration (bound plus free). If protein binding changes, the same total concentration corresponds to a different free concentration and a different pharmacological effect.

Phenytoin is the paradigmatic clinical example. The standard therapeutic range of 10 to 20 micrograms per milliliter applies to total phenytoin in patients with normal albumin (approximately 4.4 grams per deciliter). In a patient with hypoalbuminemia — as occurs in hepatic cirrhosis, nephrotic syndrome, malnutrition, or critical illness — the free fraction of phenytoin increases substantially, and a measured total phenytoin level of 8 micrograms per milliliter may represent fully adequate free drug exposure despite appearing subtherapeutic. Treating to the standard total concentration target in a hypoalbuminemic patient risks phenytoin toxicity. The corrected phenytoin concentration can be estimated using a formula that adjusts the measured total level for the patient's albumin, though the corrected value is an estimate and measurement of free phenytoin concentration is preferable when clinically important decisions are being made.

Valproic acid presents the same challenge, but with an additional complication: valproic acid binding to albumin is saturable at higher drug concentrations, meaning the free fraction increases disproportionately at high total concentrations. This non-linear relationship between total and free valproic acid is another reason total levels can be misleading in clinical practice.

When two drugs compete for the same albumin binding site, the drug with lower affinity may be displaced into the free fraction, transiently raising its unbound drug concentration. Classic pharmacology teaching attributed many clinically significant interactions to displacement; the current understanding is more nuanced.

For most drugs, displacement interactions are self-limiting and clinically minor. The displaced free drug is simultaneously more available for distribution into tissues (increasing Vd) and more available for elimination (increasing clearance). The net result is a transient rise in free drug concentration that returns toward the original steady state as distribution and elimination compensate. Displacement interactions are clinically meaningful only for drugs with all three of these characteristics simultaneously: high protein binding (above approximately 90 percent), narrow therapeutic index, and small Vd (so that the displaced fraction represents a large change in total body free drug). Warfarin meets all three criteria, which is why displacing agents such as amiodarone — combined with concurrent inhibition of warfarin's cytochrome P450 2C9-mediated metabolism — can significantly potentiate anticoagulation.

Several clinical conditions alter plasma protein concentrations enough to affect drug pharmacokinetics in a clinically important way. Hypoalbuminemia (albumin below 3.0 grams per deciliter) increases the free fraction of highly albumin-bound drugs including phenytoin, valproic acid, warfarin, and diazepam. This occurs in hepatic cirrhosis (reduced albumin synthesis), nephrotic syndrome (urinary albumin loss), severe malnutrition, and critical illness.

Alpha-1-acid glycoprotein rises up to threefold during inflammation, surgery, myocardial infarction, and other acute illnesses, increasing the bound fraction of basic drugs such as lidocaine and propranolol. In the acute postoperative state, total lidocaine or propranolol levels may appear elevated while free drug concentrations — and pharmacological effects — are actually unchanged or even reduced. Alpha-1-acid glycoprotein concentrations fall in hepatic insufficiency and are low in neonates, giving newborns higher free fractions of basic drugs at standard weight-based doses.

A loading dose is a larger-than-maintenance initial dose intended to rapidly achieve a target plasma concentration rather than waiting for the drug to accumulate to steady state through repeated maintenance dosing. The loading dose is calculated as the target plasma concentration multiplied by the volume of distribution: loading dose equals target concentration multiplied by Vd. A drug with a large Vd requires a large loading dose to fill the tissue reservoir before the desired plasma concentration is achieved.

Digoxin illustrates this principle: its Vd of approximately 7 liters per kilogram means that the tissue reservoir is enormous. To achieve a therapeutic plasma digoxin concentration rapidly (as in atrial fibrillation with rapid ventricular response), multiple intravenous loading doses are required to fill the tissue compartment before plasma concentrations reach the therapeutic range. Vancomycin loading doses in critically ill patients with expanded extracellular fluid volumes — sepsis, fluid resuscitation, edema — must be higher than for standard patients because the effective Vd for this hydrophilic drug is substantially larger. Similarly, weight-based loading doses for water-soluble drugs in obese patients should use lean body weight, not total body weight, because adipose tissue does not appreciably distribute hydrophilic drugs.

Hemodialysis and other extracorporeal removal techniques can only remove drug that is present in plasma at the time of dialysis. A drug with a small Vd, where most of the body's drug burden is in plasma, will be effectively removed by dialysis. A drug with a large Vd, where most of the body's drug burden is sequestered in tissues, will not be effectively removed by dialysis even if plasma concentrations transiently fall during the session — because drug rapidly redistributes from tissue back into plasma as soon as the session ends.

This principle is clinically important in overdose management. Lithium has a Vd of approximately 0.8 liters per kilogram and is efficiently removed by dialysis — a mainstay of management in severe lithium toxicity. Digoxin has a Vd of approximately 7 liters per kilogram and is not meaningfully removed by dialysis; treatment of digoxin toxicity relies on digoxin-specific antibody fragments, not dialysis. Tricyclic antidepressants have Vd values exceeding 20 liters per kilogram and are essentially undialyzable; management of overdose focuses on supportive care rather than drug removal.

Large Vd drugs present unique challenges in toxicology because the drug has distributed into tissues before clinical toxicity becomes apparent, and reversal of toxicity does not correlate with plasma drug level reduction. Amiodarone accumulates over months to years in tissues at concentrations far exceeding plasma, explaining why pulmonary and thyroid toxicity can persist for months after the drug is stopped. When a clinician says a drug is "out of the system" based on plasma levels being undetectable, this reasoning fails for drugs with enormous Vd where tissue concentrations remain high despite undetectable plasma levels.

In a one-compartment model, the drug is assumed to distribute instantaneously and uniformly throughout the body after administration. Following an intravenous bolus, the plasma concentration declines in a single exponential phase reflecting only elimination. Drugs that behave this way tend to be hydrophilic and distribute primarily within the extracellular fluid, reaching distribution equilibrium rapidly. For these drugs, any blood sample drawn after administration gives a concentration that reflects the drug's true distribution state, and the concentration-time curve forms a single straight line on a semi-logarithmic plot.

Many drugs, particularly lipophilic ones, exhibit two-compartment behavior. After an intravenous bolus, the concentration-time curve shows two distinct phases on a semi-logarithmic plot. The initial rapid decline — the distribution phase, also called the alpha phase — represents the drug moving rapidly from plasma into a peripheral tissue compartment. Plasma concentrations fall steeply during this phase not because the drug is being eliminated, but because it is redistributing into tissues. The subsequent slower decline — the elimination phase, also called the beta phase — represents true elimination from the body and runs at a pace governed by clearance and the equilibrium volume of distribution.

This two-phase behavior has a critically important practical implication: drug levels drawn during the distribution phase are artifactually high and do not reflect the equilibrium concentration at the site of action. Drawing a digoxin level within two hours of an intravenous dose yields a falsely elevated result because digoxin is still distributing into myocardium and other tissue; the plasma level will be far higher than what the tissue is actually experiencing. The recommended approach is to wait at least six to eight hours after an intravenous digoxin dose — until distribution is essentially complete — before drawing a clinically interpretable level.

Lidocaine is another classical example of two-compartment behavior with important clinical consequences. After an intravenous bolus for cardiac arrhythmia, plasma lidocaine concentrations fall rapidly during the distribution phase. If a repeat bolus is given based on the falling plasma concentration without recognizing that this fall reflects redistribution rather than elimination, successive boluses can lead to lidocaine accumulation and toxicity — the "flash and crash" phenomenon. This is why lidocaine is given as a bolus followed by a maintenance infusion, rather than repeated boluses, for arrhythmia management.

The concept also applies to interpreting vancomycin trough levels. Vancomycin exhibits two-compartment kinetics, and trough levels drawn at the appropriate time (30 to 60 minutes before the next dose, after distribution is complete) reflect true equilibrium concentrations and are interpretable. Vancomycin area under the curve-to-minimum inhibitory concentration ratio-guided dosing increasingly replaces simple trough monitoring, but the underlying principle — that drug levels must be drawn at a time that reflects true distribution equilibrium — remains the same regardless of the monitoring strategy.